

SYNTHESIS OF NOVEL MANNICH BASES CONTAINING PYRAZOLONES AND INDOLE SYSTEMS

**L.K.Ravindranath, K.Srikanth, M.Dastagiri Reddy and S.D.Ishrath Begum*

*Professor in Chemistry S.K.University Anantapur, Andrapradesh, India
Author to whom correspondence should be addressed -lkavindranath@gmail.com*

Abstract Novel mannich bases 7 a-h were synthesized the condensation reaction between 3-Methyl-5-oxo-4-(4'-phenyl hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid hydrazide 4 With Isatin yielded the corresponding [3-Methyl-5-oxo-4-(4'-substituted aryl hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid(2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6, this was subjected to mannich reaction with cyclic secondary amines in the presence of formaldehyde in DMF to give corresponding hydrazide 7 in excellent yields. The structures of these newly synthesized compounds were characterized by ¹H-NMR, Mass, IR and elemental analysis.

Introduction

Heterocyclic compounds represents an important class of biologically active molecules specifically, those containing the pyrazolone nucleus have been shown to possess high biological activities such as tranquillizing, muscle relaxant, psycho analeptic, anticonvulsant, antihypertensive, antidepressant activities. The derivatives of pyrazolone are important class of antipyretic and analgesic Compounds ¹⁻⁷

Medicinal chemists have been designed used pyrazolones extensively as scaffolds from which novel therapeutic agents. This heterocyclic ring system is found in a number of compounds showing analgesic morazone⁸ immunosuppressant BTS-71412⁹ and anti-inflammatory (aspirin-propyphenazone) activity. Numerous methods for general pyrazolone synthesis have been reported¹⁰


Some substituted pyrazolines and their derivatives are used as antitumor¹¹ anti bacterial, antifungal, antiviral, anti parasitic, anti-tubercular and insecticidal agents¹²⁻²⁰ some of these compounds have also anti-inflammatory, anti-diabetic, and anesthetic properties²¹⁻²³

Results and Discussion

The development of carbon- nitrogen bond formation was described in all the steps of our synthetic sequence. The advent of microwave synthesis also implemented with the improved yield of 90%. A further step involves simple reaction conditions and good yield procedure. Compound 6 was allowed to undergo the Mannich reaction with different secondary Amines namely piperidine, morpholine and N-methyl piperazine and Para formaldehyde in absolute ethanol to give compounds 7 a-c respectively.

The IR spectrum of 7 revealed the appearance of bands characteristics of 3195 (NH), 1610 (C = N), 1676 (pyrazoline C = O), 1720 (Indole C = O), and 1654 (C – NH). The appearance of a signal at δ 4.5 due to (N – CH₂– N), 3.70 (t, 4H, CH₂–O–CH₂), 2.70 (t, 4H, CH₂–N–CH₂), 4.20 (s, 3H, N–CH₃), conformed the formation of Mannich bases.

Scheme-1



- 1a, 2a, 3a, 4a, 6a, 7a R = H
 1b, 2b, 3b, 4b, 6b, 7b R = 4-CH₃
 1c, 2c, 3c, 4c, 6c, 7c R = 4-OCH₃
 1d, 2d, 3d, 4d, 6d, 7d R = 4-OC₂H₅
 1e, 2e, 3e, 4e, 6e, 7e R = 4- Cl
 1f, 2f, 3f, 4f, 6f, 7f, R=4-Br

- 7a R=H, X=CH₂
 7g R=H, X=O
 7h R=H, X=N-CH₃

General procedures

4-substituted aryl hydrazono acetoacetic ester 1 was prepared by the procedure described by H.M.W.alborsky, M.E.Baum²⁴

Condensation of 4-substituted aryl hydrazono acetoacetic ester 1 and hydrazine in the presence of catalytic amount of dimethyl formamide under microwave irradiation afforded Synthesis of 3-methyl-4- (4'-substituted aryl hydrazono)-pyrazoline-5-one 2.

A mixture of 2, anhydrous K₂CO₃, Chloro ethyl acetate and DMF were stirred at room temperature for 8 hours. The reaction mixture was diluted with ice-cold water. The separated solid was identified as 3 this was collected by filtration.

A solution of 3 and hydrazine hydrate in ethanol was refluxed for five hours. The reaction mixture was cooled and poured onto ice cold water with stirring. The separated solid was filtered, washed with water and recrystallized from ethanol to afford 4.

A mixture of 4 and 5 in 1: 1 ratio when heated in DMF (10 ml) on water bath for 45 minutes yielded a compound was filtered washed with water and recrystallized from ethanol to afford 6, the required Isatin 5 was prepared by the procedure described by Marvel and Heirs²⁵

Compounds 6 was subjected to Mannich reaction with cyclic secondary amines (piperidine) / morpholine / N-methyl piperazine) in the presence of formaldehyde in DMF to give [3-Methyl-5-oxo-4- (4'-substituted aryl hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1-piperidine-1-ylmethyl-1,2-dihydro-indol-3-ylidene)- hydrazide 7 in excellent yields.

Experimental

All the chemicals were used as received without further purification. Melting points were measured on a Gallenkamp Electro thermal melting point apparatus and are uncorrected. Reactions were carried out using household micro oven (power consumption 1200 W, microwave frequency 2450 MHz) and monitored by thin layer chromatography (TLC) on silica gel plates (60 F254) visualizing with ultraviolet light or iodine spray. ¹H NMR spectra were determined in DMSO-*d*₆ solution on 400 or 200 MHz AMX Spectrometers. Proton chemical shifts are relative to tetramethylsilane as internal standard and expressed in ppm.

Mixtures of 1 and hydrazine hydrate and dimethyl formamide (10 drops) were subjected to microwave irradiation at 150W intermittently at 30 sec intervals for 2 minutes. After complete conversion as indicated by TLC, the reaction mixture was cooled and treated with cold water. The precipitate 3-methyl 4-(4'-substituted aryl hydrazono) pyrazoline-5-one 2 was filtered and recrystallized from ethanol.

A mixture of [3-methyl-5-oxo-4- (4-substituted aryl hydrazono)-4,5-pyrazoline-5-one 2 (0.02M) anhydrous K₂CO₃ (0.03M) Chloro ethyl acetate (0.02M) and DMF was stirred at room temperature for 8 hours, the reaction mixture was diluted with ice-cold water. The separated solid was identified as 3. This was collected by filtration and recrystallized from ethanol.

A solution of 3 (0.01M) and hydrazine hydrate (0.015M) in ethanol 20 ml was refluxed for 5 hours. The reaction mixture was cooled and poured on to ice cold water with stirring. The separated solid was filtered, washed with water and recrystallized from ethanol to afford 4.

[3-Methyl-5-oxo-4-(aryl hydrazono)-4, 5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 a-f.

Equimolar quantities (0.01 mol) of Isatin 5 and the corresponding amino compound (6 a-f) were dissolved in warm ethanol (40 ml) containing DMF (0.5 ml). The reaction mixture was refluxed for 1-4 hr and then kept at room temperature overnight. The resulting solid was filtered and washed with ethanol, dried and recrystallized from ethanol to afford compounds (6a-f).

[3-Methyl-5-oxo-4-(phenyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid

(2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 a: Yield 70%, m.p. 214°C; IR (KBr disc cm^{-1}) 3205, 3170, 1602, 1670 and 1618; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 1.1 (s, 3H, CH_3) 7.2 (s, 1H, Ar - NH) 9.7 (s, 1H, CONH) 3.9 (s, 2H, N-CH_2 - CO) 10.42 (s, 1H, Indole NH) 6.4-7.6 (m, 9H, Ar -H); $^{13}\text{C-NMR}$: ($\text{DMSO-}d_6$, δ ppm): 18.6, 54.5, 116.3, 117.8, 118.8, 121.7, 124.5, 128.6, 129.4, 131.3, 133, 146.8, 148, and 167.7; EI ms: m/z: 403 Anal. Calcd. for $\text{C}_{20}\text{H}_{17}\text{N}_7\text{O}_3$ (403.39) C: 59.74; H: 4.43; N: 24.46; Found C: 59.55; H: 4.25; N: 24.31.

[3-Methyl-5-oxo-4-(p-tolyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid

(2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 b: obtained as yellow orange crystals; Yield 70%, m.p. 241°C. IR (KBr disc cm^{-1}) 3180, 3140, 1600, 1674, 1700 and 1622; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 1.14 (s, 3H, CH_3) 2.39 (s, 3H, Ar- CH_3) 7.4 (s, 1H, Ar - NH) 10.2 (s, 1H, CONH) 3.92 (s, 2H, N-CH_2 - CO) 10.47 (s, 1H, Indole NH) 6.43-7.62 (m, 8H, Ar -H); EI ms: m/z: 417.1; Anal. Calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_7\text{O}_3$ (417.42) C: 60.60; H: 4.77; N: 23.63; Found C: 60.42; H: 4.59; N: 23.49.

[4-[(4-Methoxy-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 c:

obtained as orange crystals; Yield 70%, m.p. 234°C; IR (KBr disc cm^{-1}) 3100, 3150, 1505, 1674, 1701 and 1625; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 1.12 (s, 3H, CH_3) 3.73 (s, 3H, OCH_3) 7.1 (s, 1H, Ar -NH) 10.35 (s, 1H, CONH) 4.1 (s, 2H, N-CH_2 - CO) 10.46 (s, 1H, Indole NH) 6.43-7.58 (m, 8H, Ar - H); EI ms: m/z: 433; Anal. Calcd. for $\text{C}_{21}\text{H}_{19}\text{N}_7\text{O}_4$ (433.42) C: 58.37; H: 4.32; N: 22.77. Found C: 58.19; H: 4.42; N: 22.62.

[4-[(4-Ethoxy-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 d: obtained as orange crystals; Yield 75%, m.p. 224°C; IR (KBr disc cm^{-1}) 3195, 3155, 1604, 1674, 1701 and 1624; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 0.98 (s, 3H, CH_3) 1.34 (t, 3H, CH_3) 3.96 (q, 2H, O-CH_2) 7.18 (s, 1H, Ar-NH) 10.21 (s, 1H, CONH) 4.2 (s, 2H, N-CH_2 - CO) 10.47 (s, 1H, Indole NH) 6.43-7.60 (m, 8H, Ar - H); EI ms: m/z: 447.1; Anal. Calcd. for $\text{C}_{22}\text{H}_{21}\text{N}_7\text{O}_4$ (447.45) C: 59.23; H: 4.90; N: 22.03; Found C: 59.05; H: 4.73; N: 21.91.

[4-[(4-Chloro-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 e: obtained as reddish-orange crystals; Yield 75%, m.p. 225°C; IR (KBr disc cm^{-1}) 3175, 3140, 1605, 1674, 1701 and 1624; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 1.05 (s, 3H, CH_3) 6.98 (s, 1H, Ar - NH), 10.73 (s, 1H, CONH), 3.7 (s, 2H, N-CH_2 - CO), 10.49 (s, 1H, Indole NH), 6.43-7.6 (m, 8H, Ar - H); EI ms: m/z: 437; Anal. Calcd. for $\text{C}_{20}\text{H}_{16}\text{N}_7\text{O}_3\text{Cl}$ (437.84) C: 55.02; H: 3.84; N: 22.53. Found C: 54.86; H: 3.68; N: 22.39.

[4-[(4-Bromo-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 6 f: obtained as orange brown crystals; Yield 80%, m.p. 243°C; IR (KBr disc cm^{-1}) 3190, 3150, 1605, 1673, 1702 and 1625; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, δ ppm): 1.05 (s, 3H, CH_3), 6.98 (s, 1H, Ar - NH) 10.83 (s, 1H, CONH) 3.8 (s, 2H, N-CH_2 - CO) 10.47 (s, 1H, Indole NH) 6.3-7.65 (m, 8H, Ar - H); EI ms: m/z: 481; Anal. Calcd. for $\text{C}_{20}\text{H}_{16}\text{N}_7\text{O}_3\text{Br}$ (482.29) C: 49.99; H: 3.48; N: 20.49. Found C: 49.81; H: 3.34; N: 20.33.

Synthesis of [3-methyl-5-oxo-4-(phenyl hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1-piperidine-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 a-h.

A mixture of 6 (0.1 mol), piperidine (0.15 mol) and water (20 ml) was stirred to obtain a clear solution. To this solution, HCHO (0.05 mol) and DMF were added in ice-cold condition and stirred for 2 hr in an ice-bath and left overnight at

room temperature. The obtained white solid was isolated and crystallized from ethanol. To give Compound 7 a the reaction procedure leading to 7a was then extended to the syntheses of 7b, 7c and the Spectral data of the compounds (7 a-h) are listed.

[3-Methyl-5-oxo-4-(phenyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 a: obtained as yellow-orange crystals; Yield 70%, m.p. 158 °C; IR (KBr disc cm^{-1}) 3195, 1720, 1610, 1676, 1654; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, \square ppm): 1.40-1.52 (m, 6H (CH_2)₃) 2.56-2.62 (m, 4H, $-\text{CH}_2\text{-N-CH}_2$) 4.43 (s, 2H, $-\text{N-CH}_2\text{-N-}$) 9.5 (s, $-\text{CONH}$) 7.15 (s, 1H, Ar - NH) 3.95 (s, 2H, $\text{N-CH}_2\text{-CO}$) 6.45 - 7.7 (m, 9H, Ar - H); $^{13}\text{C-NMR}$: ($\text{DMSO-}d_6$, \square ppm): 18.8, 25.6, 26.0, 51, 54.9, 70.9, 115.2, 118, 120.1, 123, 124, 129, 131, 146, 162, 173; EI ms: m/z: 500; Anal. Calcd. for $\text{C}_{26}\text{H}_{28}\text{N}_8\text{O}_3$ (500.55) C: 62.56; H: 5.78; N: 22.58; Found C: 62.39; H: 5.64; N: 22.39.

[3-Methyl-5-oxo-4-(p-tolyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 b: obtained orange crystals; Yield 70 %, m.p. 164 °C ; IR (KBr disc cm^{-1}) 3170, 1715, 1616, 1674, 1674; EI ms: m/z: 514; Anal. Calcd. for $\text{C}_{27}\text{H}_{30}\text{N}_8\text{O}_3$ (514.58) C: 63.13; H: 6.00; N: 21.96; Found C: 23.02; H: 5.88; N: 21.78.

{4-[(4-Methoxy-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl}-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 c: obtained as yellow crystals; Yield 70%, m.p. 167 °C; IR (KBr disc cm^{-1}) 3120, 1680, 1610, 1680, 1654; EI ms: m/z: 530.1; Anal. Calcd. for $\text{C}_{27}\text{H}_{30}\text{N}_8\text{O}_4$ (530.58) C: 61.27; H: 5.83; N: 21.26; Found C: 61.12; H: 5.70; N: 21.12.

{4-[(4-Ethoxy-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl}-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 d: obtained as yellow crystals; Yield 75%, m.p. 159 °C; IR (KBr disc cm^{-1}) 3175, 1711, 1614, 1674, and 1656; EI ms: m/z: 544; Anal. Calcd. for $\text{C}_{28}\text{H}_{32}\text{N}_8\text{O}_4$ (544.60) C: 61.92; H: 6.08; N: 20.72; Found C: 61.75; H: 5.92; N: 20.58.

{4-[(4-Chloro-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl}-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 e: obtained as orange crystals; Yield 75%, m.p. 161 °C; IR (KBr disc cm^{-1}) 3155, 1714, 1616, 1674, 1658; EI ms: m/z: 534; Anal. Calcd. for $\text{C}_{26}\text{H}_{27}\text{N}_8\text{O}_3\text{Cl}$ (535) C: 58.83; H: 5.24; N: 21.05. Found C: 58.70; H: 5.09; N: 20.94.

{4-[(4-Bromo-phenyl)-hydrazono]-3-methyl-5-oxo-4,5-dihydro-pyrazol-1-yl}-acetic acid (2-oxo-1-piperidin-1-ylmethyl-1,2-dihydro-indol-3-ylidene)-hydrazide 7 f: obtained as reddish-orange crystals; Yield 80%, m.p. 160 °C; IR (KBr disc cm^{-1}) 3170, 1716, 1674, 1614, 1626; EI ms: m/z: 578; Anal. Calcd. for $\text{C}_{26}\text{H}_{27}\text{N}_8\text{O}_3\text{Br}$ (579.45) C: 54.02; H: 4.84; N: 19.47. Found C: 53.89; H: 4.70; N: 19.34.

[3-Methyl-5-oxo-4-(phenyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid (1-morpholin-4-ylmethyl-2-oxo-1,2-dihydro-indol-3-ylidene)-hydrazide 7 g: obtained as orange crystals; Yield 85%, m.p. 159 °C; IR (KBr disc cm^{-1}) 3193, 1710, 1620, 1681, 1660; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$, \square ppm): 3.70-3.50 (m, 4H, $\text{CH}_2\text{-O-CH}_2$), 2.70-2.60 (m, 4H, $\text{CH}_2\text{-N-CH}_2$), 4.40 (s, 2H, $\text{N-CH}_2\text{-N-}$) 4.7 (s, 2H, $\text{N-CH}_2\text{-CO-}$) 9.2 (s, 1H, CONH) 7.35 (s, 1H, Ar - NH) 6.4 - 7.62 (m, 9H, Ar - H); EI ms: m/z: 502; Anal. Calcd. for $\text{C}_{25}\text{H}_{26}\text{N}_8\text{O}_4$ (502.53) C: 59.90; H: 5.32; N: 22.35. Found C: 59.76; H: 5.17; N: 22.31.

[3-Methyl-5-oxo-4-(phenyl-hydrazono)-4,5-dihydro-pyrazol-1-yl]-acetic acid [1-(4-methyl-piperazin-1-ylmethyl)-2-oxo-1,2-dihydro-indol-3-ylidene]-hydrazide 7 h : obtained as yellow-orange crystals; Yield 80%, m.p. 157 °C; IR (KBr disc cm^{-1}) 3180, 1710, 1617, 1666, 1657; $^1\text{H-NMR}$ (DMSO- d_6 , δ ppm): 2.62-2.71 (m, 4H, $\text{CH}_2\text{-N-CH}_2$) 2.93 (s, 3H, N-CH_3) 4.52 (s, 2H, $\text{N-CH}_2\text{-N-}$) 4.9 (s, 2H, $\text{N-CH}_2\text{-CO-}$) 9.4 (s, 1H, CONH) 7.15 (s, 1H, Ar-NH) 6.5 - 7.6 (m, 9H, Ar-H); EI ms: m/z: 515; Anal. Calcd. for $\text{C}_{26}\text{H}_{29}\text{N}_9\text{O}_3$ (515.57) C: 60.69; H: 5.75; N: 24.58; Found C: 60.58; H: 5.63; N: 24.46.

References

1. Polevoi LG: *Tr Nauchn Konf Aspir Ordin, 1-yi (Peruyi) Mosk Med Inst, Moscow 159(1964)*; *Chem Abstr* 65,9147d (1996)
2. Batulin YM: On the mechanism of the anticonvulsant action of some derivatives of Pyrazole. *Farmakol Toksikol* 31,533 (1968) *Chem. Abstr* 70,2236a (1969)
3. Parmar SS, Pandey BR, Dwivedi C, Harbinson RD: Anticonvulsant activity And Monoamine oxidase inhibitory properties of 1, 3, 5-trisubstituted pyrazolines. *J. Pharm Sci* 63, 1152 (1974)
4. Soni N, Pande K, Kalsi R, Gupta TK, Parmar SS, Barthwal JP: Inhibition of rat Brain monoamine oxidase and succinic dehydrogenase by anticonvulsant pyrazolines. *Res Commun Chem Pathol Pharmacol*, 56,129 (1987)
5. Turan-Zitouni G, Chevallet P, Kilic FS, Erol K: Synthesis of some thiazolyl-pyrazoline Derivatives and preliminary investigation of their hypotensive activity. *Eur J Med Chem* 35,635 (2000)
6. Rajendra Prasad Y, Lakshmana Rao A, Prasoona K, Murali K, Ravi Kumar P: Synthesis and antidepressant activity of some 1, 3, 5- triphenyl-2-pyrazolines and 3-(2"-Hydroxynaphthalen-1"-yl) - 1, 5-diphenyl-2-pyrazolines. *Bioorg Med Chem Lett* 15, 5030 (2005)
7. The Merck Index 10th ed., M. Windholz, Merck, Rahway, (1983)
8. Mrongovius, R.; Neugebauer, M.; Rucker, G. *Eur.J.Med.Chem* 19, 161– 166 (1984)
9. Tomkins, P. T.; Cooper, K. L.; Titchmarsh, S. A.; Appleby, P.; Webber, D. G. *J. Immuno pharmacol* 17, 357–366 (1995)
10. Aonuma, S.; Kohama, Y.; Komiyama, Y.; Fujimoto, S. *Chem. Pharm. Bull* 28, 1237–1244(1980)
11. Taylor, E. C.; Patel, H.; Kumar, H. *Tetrahedron* 48, 8089 (1992)
12. Roelfvan, S. G.; Arnold, C.; Wellnga, K. *J. Agric. Food Chem.* 1979, 84, 406.
13. Keats, G. H. *Brit. Pat.* 1,209,631 (1970)
14. Kedar, R. M.; Vidhale, N. N.; Chincholkar, M. M. *Orient. J. Chem.* 13, 143 (1997)
15. Singh, A.; Rathod, S.; Berad, B. N.; Patil, S. D.; Dosh, A. G. *Orient. J. Chem.* 16,315, (2000)
16. Katri, H. Z.; Vunii, S. A. *J. Ind. Chem. Soc.* 58, 168, (1981)
17. Das, N. B.; Mitra, A. S. *Ind. J. Chem.* 16B, 638 (1978)
18. Azarifar, D.; Shaebanzadeh, M. *Molecules* 7, 885 (2002)
19. Holla, B. Shivarama; Akberali, P. M.; Shivanada, M. K. *Farmaco* 55, 256 (2000)

20. Palaska, E.; Aytemir, M.; Tayfun, I; Erol, K. Dilek, E. *Eur. J. Med. Chem. Chim. Ther.* 36,539, (2001)
21. Garge, H. G.; Chandraprakash, *J. Pharm. Sc.* 14, 649 (1971)
22. Regaila, H. A.; El-Bayonk, A. K.; Hammad, M. *Egypt. J. Chem.* 20, 197 (1979)
23. Krishna, R.; Pande, B. R.; Bharthwal, S. P.; Parmar, S. S. *Eur. J. Med. Chem.* 15, 567 (1980)
24. H.M.Walborsky, M.E.Baum, *J.Am.Chem.Soc.* 80(1) 187-192 (1958)
25. Marvel CS and Heirs GS. *Organic Synthesis Collective Volume -1.* 2nd Ed. John Wiley & Sons, New York 423, (1941)

Received on May 20, 2009.

